Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
PHASE1CompletedINTERVENTIONAL
Enrollment
81
Participants
Timeline
Start Date
March 25, 2014
Primary Completion Date
September 2, 2021
Study Completion Date
September 2, 2021
Conditions
Acute Lymphocytic LeukemiaDiffuse Large Cell Lymphoma
Interventions
BIOLOGICAL
huCART19
Trial Locations (1)
19104
Children's Hospital of Philadelphia, Philadelphia
All Listed Sponsors
lead
University of Pennsylvania
OTHER
NCT02374333 - Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy | Biotech Hunter | Biotech Hunter